Abstract: The invention relates to the field of immuno-oncology. More in particular, it relates to applying the mixed-lineage kinase domain-like protein (MLKL) or variants thereof in immunotherapeutic treatment of cancer. The MLKL or variant thereof is inducing an adaptive immune response to cancer cells leading to treatment of primary tumors and preventing development of secondary tumor or tumor metastasis.

Abstract: The present invention discloses a composition comprising a polyelectrolyte complex and a polyol, characterised in that said polyol is in amorphous form. Optionally, the composition further comprises one or more drugs, wherein each drug has a molecular weight of at least 1000 Dalton. Said compositions are obtainable by spray-drying. The compositions may be prepared in particle form and as a suspension of particles. Pharmaceutical compositions are also provided for use in extracellular drug delivery. Pharmaceutical compositions are also provided that exhibit a controlled dual drug release.

Abstract: The present invention relates to a method of obtaining protection against, simultaneously, a specific allergen and a by-stander allergen. The method comprises the administration of a compound comprising an allergen binding domain and a Fc domain, wherein the bystander allergen is unrelated to the allergen bound by the allergen binding domain.

Abstract: The present invention relates to the production of bispecific or multispecific, bi- or tetravalent antibodies using recombinant DNA methods and recombinant production methods. The resulting antibody consists of one or two diabody molecules that are heterodimerized by creating a fusion protein with the CL and CH1 immunoglobulin constant domains.

Abstract: The present invention discloses a method to induce the CD4+ Th1 immune response, combined with a repression of the Th2 mediated activities. The method comprises administering an IgG isotype antibody, which is not an IgG1 isotype antibody. The antibody is an IgG2a and/or IgG2b isotype anti-allergen antibody. The shift from a Th2 response towards a mixed Th1/Th2 response is useful in the treatment of diseases, such as asthma. Since the disclosed method corrects the immuno-pathological cause of the disease, the polarized Th2 response against allergen, a sustained cure from asthma may be achieved.